{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:32:20Z","timestamp":1782459140506,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["R01AR074420"],"award-info":[{"award-number":["R01AR074420"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006364","name":"Department of Veterans Affairs | James A. Haley Veterans' Hospital","doi-asserted-by":"publisher","award":["BX000141"],"award-info":[{"award-number":["BX000141"]}],"id":[{"id":"10.13039\/100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006364","name":"Department of Veterans Affairs | James A. Haley Veterans' Hospital","doi-asserted-by":"publisher","award":["BX000141"],"award-info":[{"award-number":["BX000141"]}],"id":[{"id":"10.13039\/100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013678","name":"Colorado University | Cancer Center, University of Colorado","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100013678","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SPARK|REACH University of Colorado"},{"name":"Department of Veterans Affairs | James A. Haley Veterans' Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) are now the first-line treatment for patients with advanced melanoma. Despite promising clinical results, many patients fail to respond to these therapies. BH3 mimetics, a novel class of small molecule inhibitors that bind and inhibit anti-apoptotic members of the BCL2 family proteins such as BCL2 or MCL1, have been very successful in treating hematologic malignancies. However, there are limited studies on the immunomodulatory role of the BH3 mimetics. Several factors contribute to ICI resistance including myeloid-derived suppressor cells (MDSCs) that exert immunosuppressive effects through direct and indirect inhibition of antitumor immunity. Thus, targeting MDSCs to enhance antitumor immunity has the potential to enhance the efficacy of ICIs. In this study, we show that the MCL1 inhibitor S64315 reduces melanoma tumor growth in an immune cell-dependent manner in mice. Specifically, S64315 enhances antitumor immunity by reducing MDSC frequency and by promoting the activity of CD8+T cells. Additionally, human MDSCs are 10 times more sensitive to S64315 than cutaneous melanoma lines. Further, we found that a higher expression of MCL1 is associated with poor survival for patients treated with anti-PD-1. Finally, combining S64315 and anti-PD-1 significantly slowed tumor growth compared to either agent alone. Together, this proof-of-concept study demonstrates the potential of combining an MCL1 inhibitor with anti-PD-1 in the treatment of melanoma. It justifies the further development of next generation MCL1 inhibitors to improve efficacy of ICIs in treating malignant melanoma.<\/jats:p>","DOI":"10.1038\/s41419-024-06524-w","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:02:26Z","timestamp":1709910146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade"],"prefix":"10.1038","volume":"15","author":[{"given":"Nabanita","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Katsnelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya M.","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey L.","family":"Couts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline A.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"McCarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-4534","authenticated-orcid":false,"given":"Richard P.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-5753","authenticated-orcid":false,"given":"Yiqun G.","family":"Shellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"6524_CR1","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-20-0983","volume":"9","author":"FS Hodi","year":"2021","unstructured":"Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, et al. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma. Cancer Immunol Res. 2021;9:1202\u201313.","journal-title":"Cancer Immunol Res"},{"key":"6524_CR2","doi-asserted-by":"publisher","first-page":"706652","DOI":"10.3389\/fonc.2021.706652","volume":"11","author":"T Huang","year":"2021","unstructured":"Huang T, Chen X, Zhang H, Liang Y, Li L, Wei H, et al. Prognostic role of tumor mutational burden in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021;11:706652.","journal-title":"Front Oncol"},{"key":"6524_CR3","doi-asserted-by":"publisher","first-page":"880876","DOI":"10.3389\/fonc.2022.880876","volume":"12","author":"J Thornton","year":"2022","unstructured":"Thornton J, Chhabra G, Singh CK, Guzman-Perez G, Shirley CA, Ahmad N. Mechanisms of immunotherapy resistance in cutaneous melanoma: recognizing a shapeshifter. Front Oncol. 2022;12:880876.","journal-title":"Front Oncol"},{"key":"6524_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Zehir A, Berger MF, Seshan VE, et al. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase. JAMA Oncol. 2021;7:739\u201343.","journal-title":"JAMA Oncol"},{"key":"6524_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1189\/jlb.5VMR1016-449R","volume":"102","author":"RP Tobin","year":"2017","unstructured":"Tobin RP, Davis D, Jordan KR, McCarter MD. The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. J Leukoc Biol. 2017;102:381\u201391.","journal-title":"J Leukoc Biol"},{"key":"6524_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"6524_CR7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.","journal-title":"Front Immunol"},{"key":"6524_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","volume":"13","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky A, Vogler M, K\u00f6se MC, Heckman CA, Ehx G, Ludwig H, et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol. 2020;13:173.","journal-title":"J Hematol Oncol"},{"key":"6524_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65\u201380.","journal-title":"Cell Death Differ"},{"key":"6524_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28:20\u201338.","journal-title":"Apoptosis"},{"key":"6524_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14:67.","journal-title":"J Hematol Oncol"},{"key":"6524_CR12","doi-asserted-by":"publisher","first-page":"864874","DOI":"10.3389\/fmolb.2022.864874","volume":"9","author":"V Sora","year":"2022","unstructured":"Sora V, Papaleo E. Structural details of BH3 motifs and BH3-mediated interactions: an updated perspective. Front Mol Biosci. 2022;9:864874.","journal-title":"Front Mol Biosci"},{"key":"6524_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1407-6","volume":"10","author":"CFA Warren","year":"2019","unstructured":"Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019;10:177.","journal-title":"Cell Death Dis"},{"key":"6524_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11:941.","journal-title":"Cell Death Dis"},{"key":"6524_CR15","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/jid.2015.145","volume":"135","author":"N Mukherjee","year":"2015","unstructured":"Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG. Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells. J Invest Dermatol. 2015;135:2155\u201361.","journal-title":"J Invest Dermatol"},{"key":"6524_CR16","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.3390\/cancers13174363","volume":"13","author":"CM Neophytou","year":"2021","unstructured":"Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 2021;13:4363.","journal-title":"Cancers (Basel)"},{"key":"6524_CR17","doi-asserted-by":"publisher","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","volume":"12","author":"S Qian","year":"2022","unstructured":"Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022;12:985363.","journal-title":"Front Oncol"},{"key":"6524_CR18","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.18632\/oncotarget.2792","volume":"6","author":"MM Williams","year":"2015","unstructured":"Williams MM, Cook RS. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget. 2015;6:3519\u201330.","journal-title":"Oncotarget"},{"key":"6524_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"6524_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, et al. Venetoclax enhances T cell\u2013mediated antileukemic activity by increasing ROS production. Blood. 2021;138:234\u201345.","journal-title":"Blood"},{"key":"6524_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12409-w","volume":"10","author":"MJ Sale","year":"2019","unstructured":"Sale MJ, Minihane E, Monks NR, Gilley R, Richards FM, Schifferli KP, et al. Targeting melanoma\u2019s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1\/2 pathway inhibitors. Nat Commun. 2019;10:5167.","journal-title":"Nat Commun"},{"key":"6524_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1568-3","volume":"10","author":"EF Lee","year":"2019","unstructured":"Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10:342.","journal-title":"Cell Death Dis"},{"key":"6524_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0932-z","volume":"9","author":"N Mukherjee","year":"2018","unstructured":"Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, et al. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis. 2018;9:907.","journal-title":"Cell Death Dis"},{"key":"6524_CR24","doi-asserted-by":"publisher","first-page":"40535","DOI":"10.18632\/oncotarget.5755","volume":"6","author":"NM Fofaria","year":"2015","unstructured":"Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1\/2 inhibitors in melanoma. Oncotarget. 2015;6:40535\u201356.","journal-title":"Oncotarget"},{"key":"6524_CR25","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.4049\/jimmunol.1301369","volume":"192","author":"PS Kim","year":"2014","unstructured":"Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, et al. Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol. 2014;192:2622\u201333.","journal-title":"J Immunol"},{"key":"6524_CR26","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3390\/cancers12082182","volume":"12","author":"N Mukherjee","year":"2020","unstructured":"Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, et al. Simultaneously inhibiting BCL2 and MCL1 is a therapeutic option for patients with advanced melanoma. Cancers. 2020;12:2182.","journal-title":"Cancers"},{"key":"6524_CR27","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jid.2021.11.035","volume":"142","author":"N Mukherjee","year":"2022","unstructured":"Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, et al. Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics. J Invest Dermatol. 2022;142:1912\u201322.e7.","journal-title":"J Invest Dermatol"},{"key":"6524_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2646-2","volume":"11","author":"N Mukherjee","year":"2020","unstructured":"Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, et al. MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020;11:443.","journal-title":"Cell Death Dis"},{"key":"6524_CR29","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00262-018-2196-y","volume":"67","author":"L Barrera","year":"2018","unstructured":"Barrera L, Montes-Servin E, Hernandez-Martinez JM, Orozco-Morales M, Montes-Servin E, Michel-Tello D, et al. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer. Cancer Immunol Immunother. 2018;67:1393\u2013406.","journal-title":"Cancer Immunol Immunother"},{"key":"6524_CR30","doi-asserted-by":"publisher","first-page":"37931","DOI":"10.18632\/oncotarget.9270","volume":"7","author":"M Binsfeld","year":"2016","unstructured":"Binsfeld M, Muller J, Lamour V, De Veirman K, De Raeve H, Bellahcene A, et al. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget. 2016;7:37931\u201343.","journal-title":"Oncotarget"},{"key":"6524_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","volume":"63","author":"RP Tobin","year":"2018","unstructured":"Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018;63:282\u201391.","journal-title":"Int Immunopharmacol"},{"key":"6524_CR32","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/cells10051170","volume":"10","author":"M Krishnamoorthy","year":"2021","unstructured":"Krishnamoorthy M, Gerhardt L, Maleki Vareki S. Immunosuppressive effects of myeloid-derived suppressor cells in cancer and immunotherapy. Cells. 2021;10:1170.","journal-title":"Cells"},{"key":"6524_CR33","doi-asserted-by":"publisher","first-page":"27478","DOI":"10.18632\/oncotarget.4393","volume":"6","author":"C Sorrentino","year":"2015","unstructured":"Sorrentino C, Miele L, Porta A, Pinto A, Morello S. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget. 2015;6:27478\u201389.","journal-title":"Oncotarget"},{"key":"6524_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","volume":"9","author":"RP Tobin","year":"2019","unstructured":"Tobin RP, Jordan KR, Kapoor P, Spongberg E, Davis D, Vorwald VM, et al. IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients. Front Oncol. 2019;9:1223.","journal-title":"Front Oncol"},{"key":"6524_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21:184.","journal-title":"Mol Cancer"},{"key":"6524_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun"},{"key":"6524_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3\u20138.","journal-title":"Cancer Immunol Res"},{"key":"6524_CR38","doi-asserted-by":"publisher","first-page":"740890","DOI":"10.3389\/fimmu.2021.740890","volume":"12","author":"SH Sun","year":"2021","unstructured":"Sun SH, Benner B, Savardekar H, Lapurga G, Good L, Abood D, et al. Effect of immune checkpoint blockade on myeloid-derived suppressor cell populations in patients with melanoma. Front Immunol. 2021;12:740890.","journal-title":"Front Immunol"},{"key":"6524_CR39","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138:1120\u201336.","journal-title":"Blood"},{"key":"6524_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/ph14080749","volume":"14","author":"CR Dart","year":"2021","unstructured":"Dart CR, Mukherjee N, Amato CM, Goulding A, MacBeth M, Van Gulick R, et al. A novel regimen for treating melanoma: MCL1 inhibitors and azacitidine. Pharmceuticals. 2021;14:749.","journal-title":"Pharmceuticals"},{"key":"6524_CR41","doi-asserted-by":"publisher","first-page":"84594","DOI":"10.18632\/oncotarget.13141","volume":"7","author":"N Mukherjee","year":"2016","unstructured":"Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, et al. Combining a GSI and BCL-2 inhibitor to overcome melanoma\u2019s resistance to current treatments. Oncotarget. 2016;7:84594\u2013607.","journal-title":"Oncotarget"},{"key":"6524_CR42","doi-asserted-by":"publisher","first-page":"46801","DOI":"10.18632\/oncotarget.8695","volume":"8","author":"N Mukherjee","year":"2017","unstructured":"Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, et al. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017;8:46801\u201317.","journal-title":"Oncotarget"},{"key":"6524_CR43","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/jid.2014.464","volume":"135","author":"N Mukherjee","year":"2015","unstructured":"Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, et al. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015;135:842\u201350.","journal-title":"J Invest Dermatol"},{"key":"6524_CR44","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41401-023-01079-6","volume":"44","author":"SA Kov\u00e1cs","year":"2023","unstructured":"Kov\u00e1cs SA, Fekete JT, Gy\u0151rffy B. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharm Sin. 2023;44:1879\u201389.","journal-title":"Acta Pharm Sin"},{"key":"6524_CR45","first-page":"149","volume":"7","author":"M Pelleitier","year":"1975","unstructured":"Pelleitier M, Montplaisir S. The nude mouse: a model of deficient T-cell function. Methods Achiev Exp Pathol. 1975;7:149\u201366.","journal-title":"Methods Achiev Exp Pathol"},{"key":"6524_CR46","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1002\/cam4.2113","volume":"8","author":"Q Song","year":"2019","unstructured":"Song Q, Hawkins GA, Wudel L, Chou PC, Forbes E, Pullikuth AK, et al. Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. Cancer Med. 2019;8:3072\u201385.","journal-title":"Cancer Med"},{"key":"6524_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.omto.2022.09.008","volume":"27","author":"W Yao","year":"2022","unstructured":"Yao W, Liu X, He Y, Tian M, Lu S, Wang Q, et al. ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma. Mol Ther Oncolytics. 2022;27:48\u201360.","journal-title":"Mol Ther Oncolytics"},{"key":"6524_CR48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43:546\u201363.","journal-title":"Trends Immunol"},{"key":"6524_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73552-9","volume":"10","author":"S Coletta","year":"2020","unstructured":"Coletta S, Salvi V, Della Bella C, Bertocco A, Lonardi S, Trevellin E, et al. The immune receptor CD300e negatively regulates T cell activation by impairing the STAT1-dependent antigen presentation. Sci Rep. 2020;10:16501.","journal-title":"Sci Rep"},{"key":"6524_CR50","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/2159-8290.CD-22-1338","volume":"13","author":"L Zhao","year":"2023","unstructured":"Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre CA, et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 2023;13:2448\u201369.","journal-title":"Cancer Discov"},{"key":"6524_CR51","doi-asserted-by":"publisher","first-page":"114544","DOI":"10.1016\/j.bcp.2021.114544","volume":"188","author":"JT Chiou","year":"2021","unstructured":"Chiou JT, Lee YC, Huang CH, Wang LJ, Shi YJ, Chang LS. Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells. Biochem Pharm. 2021;188:114544.","journal-title":"Biochem Pharm"},{"key":"6524_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. Cancer Discov. 2021;11:68\u201379.","journal-title":"Cancer Discov"},{"key":"6524_CR53","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/ijc.25177","volume":"127","author":"B Farsaci","year":"2010","unstructured":"Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, Schlom J, et al. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer. 2010;127:1603\u201313.","journal-title":"Int J Cancer"},{"key":"6524_CR54","doi-asserted-by":"publisher","first-page":"e86014","DOI":"10.1172\/jci.insight.86014","volume":"1","author":"RS Dronca","year":"2016","unstructured":"Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, et al. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016;1:e86014.","journal-title":"JCI Insight"},{"key":"6524_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.immuni.2017.12.014","volume":"48","author":"MD Sharma","year":"2018","unstructured":"Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, et al. Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c(+)CD103(+) Monocytic Antigen-Presenting Cells in Tumors. Immunity. 2018;48:91\u2013106.e6.","journal-title":"Immunity"},{"key":"6524_CR56","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","volume":"29","author":"RP Tobin","year":"2023","unstructured":"Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, et al. Targeting MDSC Differentiation Using ATRA: A Phase I\/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023;29:1209\u201319.","journal-title":"Clin Cancer Res"},{"key":"6524_CR57","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1158\/1078-0432.CCR-16-1784","volume":"23","author":"GA Dominguez","year":"2017","unstructured":"Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, et al. Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. Clin Cancer Res. 2017;23:2942\u201350.","journal-title":"Clin Cancer Res"},{"key":"6524_CR58","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.isci.2020.101015","volume":"23","author":"ML Rasmussen","year":"2020","unstructured":"Rasmussen ML, Taneja N, Neininger AC, Wang L, Robertson GL, Riffle SN, et al. MCL-1 Inhibition by Selective BH3 Mimetics Disrupts Mitochondrial Dynamics Causing Loss of Viability and Functionality of Human Cardiomyocytes. iScience. 2020;23:101015.","journal-title":"iScience"},{"key":"6524_CR59","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1159\/000518128","volume":"15","author":"B Calderon","year":"2021","unstructured":"Calderon B, Stancu A, Vanel FR, Vazquez L. Pembrolizumab Treatment-Induced Liver Toxicity. Case Rep. Gastroenterol. 2021;15:742\u201350.","journal-title":"Case Rep. Gastroenterol"},{"key":"6524_CR60","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","volume":"27","author":"D Remash","year":"2021","unstructured":"Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol. 2021;27:5376\u201391.","journal-title":"World J Gastroenterol"},{"key":"6524_CR61","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N. Engl J Med. 2017;377:1824\u201335.","journal-title":"N. Engl J Med"},{"key":"6524_CR62","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","volume":"11","author":"L Shojaie","year":"2021","unstructured":"Shojaie L, Ali M, Iorga A, Dara L. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B. 2021;11:3727\u201339.","journal-title":"Acta Pharm Sin B"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06524-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:04:00Z","timestamp":1709910240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06524-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["6524"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06524-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"4 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DAN, NM, MDM, RPT, and YGS have intellectual property related to the use of BH3 mimetics in cancer. All other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patient studies were conducted in accordance with the Declaration of Helsinki, Belmont Report, and U.S Common Rule. All patients were consented under approval from the Colorado Institutional Review Board (COMIRB #05-0309 and #17-2159) and provided written consent for the utilization of samples for data collection and publication. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Colorado Denver (protocol #318).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"198"}}